Lorlatinib‐induced visual and auditory hallucinations: A case report

Jun Hakamata,Hideo Nakada,Hiroshi Muramatsu,Keita Masuzawa,Hideki Terai,Shinnosuke Ikemura,Koichi Fukunaga,Tohru Aomori

Lorlatinib‐induced visual and auditory hallucinations: A case report

2021

Jun Hakamata
Hideo Nakada
Hiroshi Muramatsu
Keita Masuzawa
Hideki Terai
Shinnosuke Ikemura
Koichi Fukunaga
Tohru Aomori

Lorlatinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor for the treatment of non-small-cell lung cancer. We report a case in which visual and auditory hallucinations developed while receiving lorlatinib.

Keywords:

Medicine
Cancer research
Lung cancer
Anaplastic lymphoma kinase
Lorlatinib
Tyrosine-kinase inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations